4594 — BrightPath Biotherapeutics Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for BrightPath Biotherapeutics Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2.5	15.4	5.28	0.072	1.13
Cost of Revenue
Gross Profit	1.36	12.1	3.38	0.054	1.1
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,714	1,491	1,482	1,162	1,148
Operating Profit	-1,711	-1,476	-1,477	-1,162	-1,147
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1,717	-1,482	-1,484	-1,166	-1,149
Provision for Income Taxes
Net Income After Taxes	-1,720	-1,484	-1,486	-1,168	-1,151
Net Income Before Extraordinary Items
Net Income	-1,720	-1,484	-1,486	-1,168	-1,151
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-1,720	-1,484	-1,486	-1,168	-1,151
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-36.4	-28.5	-24.8	-18.1	-14.2
Dividends per Share